Allele frequencies in clinically distinct subgroups of the CLL cohort
CLL subgroup . | Allele frequency . | P vs CLL . | P vs counterpart . | ||
---|---|---|---|---|---|
No. . | C . | G . | |||
Sex | |||||
Female | 105 | 0.82 | 0.18 | .38 | .12 |
Male | 143 | 0.77 | 0.23 | .56 | .04 |
Binet stage | |||||
A+C | 195 | 0.80 | 0.20 | .43 | .03 |
B | 49 | 0.74 | 0.26 | .40 | .27 |
Affected LN areas | |||||
2 or less | 188 | 0.81 | 0.19 | .50 | <.001 |
More than 2 | 50 | 0.66 | 0.34 | .14 | .051 |
Spleen size | |||||
Normal | 191 | 0.81 | 0.19 | .29 | <.001 |
Enlarged | 51 | 0.72 | 0.28 | .11 | .027 |
LDH | |||||
450 IU/L or less | 192 | 0.81 | 0.19 | .01 | .003 |
More than 450 IU/L | 34 | 0.65 | 0.35 | .64 | <.001 |
Lines of therapy | |||||
Less than 2 | 170 | 0.81 | 0.19 | .41 | <.001 |
2 or more | 67 | 0.72 | 0.28 | .11 | .018 |
CLL subgroup . | Allele frequency . | P vs CLL . | P vs counterpart . | ||
---|---|---|---|---|---|
No. . | C . | G . | |||
Sex | |||||
Female | 105 | 0.82 | 0.18 | .38 | .12 |
Male | 143 | 0.77 | 0.23 | .56 | .04 |
Binet stage | |||||
A+C | 195 | 0.80 | 0.20 | .43 | .03 |
B | 49 | 0.74 | 0.26 | .40 | .27 |
Affected LN areas | |||||
2 or less | 188 | 0.81 | 0.19 | .50 | <.001 |
More than 2 | 50 | 0.66 | 0.34 | .14 | .051 |
Spleen size | |||||
Normal | 191 | 0.81 | 0.19 | .29 | <.001 |
Enlarged | 51 | 0.72 | 0.28 | .11 | .027 |
LDH | |||||
450 IU/L or less | 192 | 0.81 | 0.19 | .01 | .003 |
More than 450 IU/L | 34 | 0.65 | 0.35 | .64 | <.001 |
Lines of therapy | |||||
Less than 2 | 170 | 0.81 | 0.19 | .41 | <.001 |
2 or more | 67 | 0.72 | 0.28 | .11 | .018 |